Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.

652 patients
- 346 myelodysplastic syndromes
- 53 myelodysplastic/myeloproliferative neoplasms
- 253 controls

Flow cytometry staining
- CD45
- CD34
- CD10
- CD19
- CD5
- CD7
- CD56

Assessment of Ogata’s score
Specificity of Ogata score 89%

Sensitivity
- Low risk myelodysplastic syndromes: 54% (66%)
- Refractory anemia with excess of blasts: 88% (97%)
- Myelodysplastic/myeloproliferative neoplasms: 74% (89%)

Bardet et al., Haematologica, 2015